Dukes B期大肠癌患者术后辅助化疗的疗效评价

目的：探讨Dukes B期大肠癌患者根治性手术后辅助化疗的疗效及安全性。方法：选取102例已行根治手术的Dukes B期大肠癌患者进行分析。结果：辅助化疗组和单纯手术组患者3年无瘤生存率分别为80．0％和62．5％（P=0．019）；5年生存率分别为89．9％和66．7％（P=0．0129）。FCF辅助化疗的不良反应为食欲不振、恶心呕吐、脱发和局部色素沉着．多为1～2度。结论：Dukes B期大肠癌根治术后给予FCF方案辅助化疗能够提高患者3年无瘤生存率和5年生存率；3度不良反应发生率低、安全性好，患者耐受性好。

The Studies onAdjuvant Chemotherapy for Dukes B Colorectal Carcinoma

Objective: To evaluated the efficacy and safety of the postoperative adjuvant FCF chemotherapy for patients with colorectal carcinoma(Dukes B). Methods: A total of 102 patients with Dukes B stage bowel carcinoma, who had undergone curative resection alone(CRA group) or received FCF-based postoperative adjuvant chemotherapy(FCF group), were reviewed. The end-point was 5-year survival rate and 3-year disease-free survival rate. The side effects were recorded. Results: After a median follow-up of 41 months, The rate of 3-year disease-free survival was 80.0%and 62.5%(P=0.019) respectively for the FCF group and CRA group. The 5-year survival rate for patients with Dukes B stage colorectal carcinoma in each group was 89.97% and 66.73%(P<0.05) respectively for the FCF group and CRA group. The main side effects include anorexia, nausea/vomiting, alopecia and pigmentation. Most of the side effects were tolerable and mild. Conclusion: Postoperative adjuvant FCF chemotherapy improves 3-year disease- free survival rate and the 5-year survival rate of the patients with Dukes B stage colorectal carcinoma. The regimens of FCF are tolerant and safe.